What is the share price of Lincoln Pharmaceuticals Ltd (LINCOLN) today?
The share price of LINCOLN as on 5th December 2025 is ₹493.15. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Lincoln Pharmaceuticals Ltd (LINCOLN) share?
The past returns of Lincoln Pharmaceuticals Ltd (LINCOLN) share are- Past 1 week: -4.08%
- Past 1 month: -5.70%
- Past 3 months: -11.73%
- Past 6 months: -13.82%
- Past 1 year: -46.57%
- Past 3 years: 41.41%
- Past 5 years: 111.61%
What are the peers or stocks similar to Lincoln Pharmaceuticals Ltd (LINCOLN)?
The peers or stocks similar to Lincoln Pharmaceuticals Ltd (LINCOLN) include:What is the dividend yield % of Lincoln Pharmaceuticals Ltd (LINCOLN) share?
The current dividend yield of Lincoln Pharmaceuticals Ltd (LINCOLN) is 0.36.What is the market cap of Lincoln Pharmaceuticals Ltd (LINCOLN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹991.67 Cr as of 5th December 2025.What is the 52 week high and low of Lincoln Pharmaceuticals Ltd (LINCOLN) share?
The 52-week high of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹979.50 and the 52-week low is ₹490.What is the PE and PB ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) stock?
The P/E (price-to-earnings) ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) is 12.04. The P/B (price-to-book) ratio is 1.48.Which sector does Lincoln Pharmaceuticals Ltd (LINCOLN) belong to?
Lincoln Pharmaceuticals Ltd (LINCOLN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Lincoln Pharmaceuticals Ltd (LINCOLN) shares?
You can directly buy Lincoln Pharmaceuticals Ltd (LINCOLN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Lincoln Pharmaceuticals Ltd
LINCOLN Share Price
493.150.39% (-1.95)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
LINCOLN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LINCOLN Performance & Key Metrics
LINCOLN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 12.40 | 1.48 | 0.36% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
LINCOLN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
LINCOLN Company Profile
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
LINCOLN Sentiment Analysis
LINCOLN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
LINCOLN Stock Summary · May 2024
The company is strategically expanding its market presence in the EU, Canada, and Australia, while maintaining a strong commitment to operational efficiency and regulatory compliance. Despite facing challenges such as increased debtor days and rising material costs, management remains optimistic about achieving a targeted annual growth rate of 15% to 18% and aims to reach INR 1,000 crores in revenue over the next three years. Investments in green energy and a focus on high-demand therapeutic areas like cardiology and diabetes underscore its commitment to sustainable growth. Additionally, the successful commercialization of the Cephalosporin plant positions the company to capitalize on rising antibiotic needs, further enhancing its revenue potential. Overall, the sentiment reflects a balanced approach to navigating operational challenges while pursuing ambitious growth objectives.
LINCOLN Stock Growth Drivers
LINCOLN Stock Growth Drivers
8Market Expansion and International Presence
The company has successfully expanded its operations into 60 countries and over 13-15 states in
Commitment to Quality and Compliance
The company has consistently upgraded its products and manufacturing practices in line with WHO guidelines
LINCOLN Stock Challenges
LINCOLN Stock Challenges
5Decline in Gross Margins
The company has experienced a significant decline in gross margins, with a drop from 57%
Operating Margin Concerns
Operating margins have shown a downward trend, decreasing from 17% in March 2022 to 15%
LINCOLN Forecast
LINCOLN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
LINCOLN
LINCOLN
Income
Balance Sheet
Cash Flow
Annual Normal View
LINCOLN Income Statement
LINCOLN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 362.99 | 366.07 | 371.78 | 397.53 | 429.85 | 482.12 | 532.78 | 614.97 | 645.71 | 656.76 | ||||||||||
Raw Materials | 224.23 | 195.49 | 164.92 | 191.33 | 193.75 | 232.15 | 245.64 | 284.04 | 282.48 | 532.55 | ||||||||||
| Power & Fuel Cost | 5.92 | 6.82 | 7.21 | 8.18 | 7.10 | 8.33 | 10.25 | 11.47 | 11.66 | |||||||||||
| Employee Cost | 37.59 | 51.15 | 51.90 | 58.65 | 63.26 | 79.72 | 93.16 | 102.90 | 112.45 | |||||||||||
| Selling & Administrative Expenses | 36.71 | 40.96 | 44.28 | 50.88 | 51.00 | 50.90 | 54.46 | 61.00 | 75.28 | |||||||||||
| Operating & Other expenses | 9.03 | 13.87 | 30.60 | 11.92 | 21.90 | 5.54 | 17.60 | 21.23 | 39.87 | |||||||||||
EBITDA | 49.51 | 57.78 | 72.87 | 76.57 | 92.84 | 105.48 | 111.67 | 134.33 | 123.97 | 124.21 | ||||||||||
| Depreciation/Amortization | 5.51 | 6.11 | 6.68 | 7.33 | 7.56 | 8.09 | 9.17 | 10.62 | 12.90 | 13.55 | ||||||||||
| PBIT | 44.00 | 51.67 | 66.19 | 69.24 | 85.28 | 97.39 | 102.50 | 123.71 | 111.07 | 110.66 | ||||||||||
| Interest & Other Items | 6.66 | 5.41 | 4.00 | 2.02 | 1.56 | 1.45 | 2.03 | 1.46 | 1.88 | 1.54 | ||||||||||
| PBT | 37.34 | 46.26 | 62.19 | 67.22 | 83.72 | 95.94 | 100.47 | 122.25 | 109.19 | 109.12 | ||||||||||
| Taxes & Other Items | 9.21 | 11.62 | 13.48 | 15.80 | 21.47 | 26.58 | 27.58 | 28.93 | 26.85 | 29.13 | ||||||||||
| Net Income | 28.13 | 34.64 | 48.71 | 51.42 | 62.25 | 69.36 | 72.89 | 93.32 | 82.34 | 79.99 | ||||||||||
| EPS | 15.49 | 17.32 | 24.35 | 25.71 | 31.10 | 34.63 | 36.39 | 46.59 | 41.11 | 39.94 | ||||||||||
| DPS | 1.20 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.80 | 1.80 | 1.80 | ||||||||||
| Payout ratio | 0.08 | 0.09 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 |
LINCOLN Company Updates
LINCOLN Stock Peers
LINCOLN Past Performance & Peer Comparison
LINCOLN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | 12.04 | 1.48 | 0.36% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
LINCOLN Stock Price Comparison
Compare LINCOLN with any stock or ETFCompare LINCOLN with any stock or ETF
LINCOLN
LINCOLN Holdings
LINCOLN Shareholdings
LINCOLN Promoter Holdings Trend
LINCOLN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LINCOLN Institutional Holdings Trend
LINCOLN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
LINCOLN Shareholding Pattern
LINCOLN Shareholding Pattern
LINCOLN Shareholding History
LINCOLN Shareholding History
Foreign Institutions
Mutual Funds Invested in LINCOLN
Mutual Funds Invested in LINCOLN
No mutual funds holding trends are available
Top 1 Mutual Funds holding Lincoln Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0007% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 105/124 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing LINCOLN stock
smallcases containing LINCOLN stock
Looks like this stock is not in any smallcase yet.
LINCOLN Events
LINCOLN Events
LINCOLN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LINCOLN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.64 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LINCOLN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LINCOLN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.64 every year
LINCOLN Upcoming Dividends
LINCOLN Upcoming Dividends
No upcoming dividends are available
LINCOLN Past Dividends
LINCOLN Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹1.80
Dividend/Share
₹1.80
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 13, 2024
Final
Final | Div/Share: ₹1.80
Dividend/Share
₹1.80
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2021
LINCOLN Stock News & Opinions
LINCOLN Stock News & Opinions
Articles & Videos
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 24.12% in the September 2025 quarter
Net profit of Lincoln Pharmaceuticals declined 24.12% to Rs 19.98 crore in the quarter ended September 2025 as against Rs 26.33 crore during the previous quarter ended September 2024. Sales rose 1.33% to Rs 163.36 crore in the quarter ended September 2025 as against Rs 161.21 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales163.36161.21 1 OPM %15.5717.60 - PBDT32.4338.01 -15 PBT28.8134.78 -17 NP19.9826.33 -24 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Lincoln Pharmaceuticals declines after weak Q2 performance
EBITDA fell by 14.86% to Rs 32.66 crore in Q2 FY26 from Rs 38.35 crore in Q2 FY25. Profit before tax in Q2 FY26 stood at Rs 28.81 crore, down by 17.17% from Rs 34.78 crore recorded in Q2 FY25. Lincoln Pharmaceuticals stated that the company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Mahendra Patel, managing director, Lincoln Pharmaceuticals, said: We are pleased to report another strong quarter, reflecting our continued focus on sustainable growth and value creation. Our growth momentum is supported by expansion into high-value therapeutic segments such as cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets. The commissioning of our Bulk Drug Manufacturing Plant and progress at our Cephalosporin facility further strengthen our backward integration and export capabilities. With a debt-free balance sheet, we are well positioned to deliver sustainable, profitable growth and enhance long-term shareholder value. Lincoln Pharmaceuticals has been manufacturing pharmaceutical formulations in the domestic market as well as exporting formulations. The company is part of the Lincoln Group, which manufactures pharmaceuticals formulations in categories such as generics, anti-malarial, anti-diabetic, gynaecology products, vitamins, minerals and anti-oxidants. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals to discuss results
Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals AGM scheduled
Lincoln Pharmaceuticals announced that the 31st Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit rises 16.94% in the June 2025 quarter
Net profit of Lincoln Pharmaceuticals rose 16.94% to Rs 27.68 crore in the quarter ended June 2025 as against Rs 23.67 crore during the previous quarter ended June 2024. Sales rose 4.61% to Rs 154.07 crore in the quarter ended June 2025 as against Rs 147.28 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales154.07147.28 5 OPM %15.4515.43 - PBDT38.8732.70 19 PBT35.3929.48 20 NP27.6823.67 17 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals announces board meeting date
Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board of Lincoln Pharmaceuticals recommends final dividend
Lincoln Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 1.8 per equity Share (i.e. 18%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 37.74% in the March 2025 quarter
Net profit of Lincoln Pharmaceuticals declined 37.74% to Rs 11.58 crore in the quarter ended March 2025 as against Rs 18.60 crore during the previous quarter ended March 2024. Sales rose 18.03% to Rs 168.18 crore in the quarter ended March 2025 as against Rs 142.49 crore during the previous quarter ended March 2024. For the full year,net profit declined 11.74% to Rs 82.35 crore in the year ended March 2025 as against Rs 93.30 crore during the previous year ended March 2024. Sales rose 7.35% to Rs 623.23 crore in the year ended March 2025 as against Rs 580.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales168.18142.49 18 623.23580.55 7 OPM %15.8912.90 -16.2817.21 - PBDT19.4724.90 -22 122.09132.87 -8 PBT16.2522.22 -27 109.19122.24 -11 NP11.5818.60 -38 82.3593.30 -12 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals to declare Quarterly Results
Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 25.93% in the December 2024 quarter
Net profit of Lincoln Pharmaceuticals declined 25.93% to Rs 20.77 crore in the quarter ended December 2024 as against Rs 28.04 crore during the previous quarter ended December 2023. Sales rose 0.07% to Rs 146.55 crore in the quarter ended December 2024 as against Rs 146.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales146.55146.45 0 OPM %16.1420.25 - PBDT31.9140.52 -21 PBT28.6837.71 -24 NP20.7728.04 -26 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.19%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 0.16% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 9.87%, vs industry avg of 20.02%